DelveInsight’s “Community-Acquired Bacterial Pneumonia (CABP) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Community-Acquired Bacterial Pneumonia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Community-Acquired Bacterial Pneumonia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Community-Acquired Bacterial Pneumonia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Community-Acquired Bacterial Pneumonia: An Overview
Community-Acquired Bacterial Pneumonia (CABP) is defined as an acute bacterial infection of the pulmonary parenchyma associated with chest pain, cough, sputum production, difficulty breathing, chills, rigors, fever, or hypotension and is accompanied by the presence of a new lobar or multilobar infiltrate on a chest radiograph.
Common typical bacterial pathogens that cause CABP include Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis. Atypical bacterial pathogens such as Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila also cause CABP.
CABP symptoms include shortness of breath, coughing, heavy sputum, fever and chills, chest pain that is worse when you breathe or cough, and upper belly (abdomen) pain with nausea, vomiting, or diarrhea. Diagnosis includes several tests: Chest X-ray, which often confirms the diagnosis, blood tests for infection and oxygen status of blood, blood culture tests, and sputum tests.
Community-Acquired Bacterial Pneumonia Market Key Facts
The total 7MM Incident cases of Community-Acquired Bacterial Pneumonia (CABP) were 6,961,838 in 2022.
The estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases. (Regunath et al., 2020)
Worldwide, CAP affects 3–4 million people each year with high morbidity and mortality, particularly among elderly patients. The WHO Global Burden of Disease study reported that lower respiratory tract infections (LRTIs), including CAP, cause approximately 429.2 million episodes of illness globally. (Sharma et al. 2020)
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Community-Acquired Bacterial Pneumonia pipeline therapies. It also thoroughly assesses the Community-Acquired Bacterial Pneumonia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Community-Acquired Bacterial Pneumonia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Community-Acquired Bacterial Pneumonia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Community-Acquired Bacterial Pneumonia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Community-Acquired Bacterial Pneumonia (CABP) Epidemiology, Segmented as –
Total Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM (2019–2032)
Diagnosed and Treatable Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM (2019–2032)
Age-specific Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM (2019–2032)
Gender-specific Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM (2019–2032)
Community-Acquired Bacterial Pneumonia (CABP) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Community-Acquired Bacterial Pneumonia market or expected to be launched during the study period. The analysis covers the Community-Acquired Bacterial Pneumonia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Community-Acquired Bacterial Pneumonia drugs based on their sale and market share.
The report also covers the Community-Acquired Bacterial Pneumonia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Community-Acquired Bacterial Pneumonia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Community-Acquired Bacterial Pneumonia Market Will Evolve and Grow by 2032 @
Community-Acquired Bacterial Pneumonia (CABP) Companies Actively Working in the Therapeutics Market Include
Some of the key companies in the Community-Acquired Bacterial Pneumonia market include Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, TiGenix and others.
Emerging and Marketed Community-Acquired Bacterial Pneumonia (CABP) Therapies Covered in the Report Include:
CAL02: Eagle Pharmaceutical
Xenleta (lefamulin): Nabriva Therapeutics
Gelsolin: BioAegis Therapeutics
And Many More
“On June 14, 2023, Eagle Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act and Fast Track Designation for CAL02, a first-in-class non-biological bacterial virulence neutralizer, the anti-infective agent being developed to treat severe community-acquired bacterial pneumonia (SCABP) as an add-on therapy to standard of care.”
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Community-Acquired Bacterial Pneumonia Competitive Intelligence Analysis
4. Community-Acquired Bacterial Pneumonia Market Overview at a Glance
5. Community-Acquired Bacterial Pneumonia Disease Background and Overview
6. Community-Acquired Bacterial Pneumonia Patient Journey
7. Community-Acquired Bacterial Pneumonia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Community-Acquired Bacterial Pneumonia Treatment Algorithm, Current Treatment, and Medical Practices
9. Community-Acquired Bacterial Pneumonia Unmet Needs
10. Key Endpoints of Community-Acquired Bacterial Pneumonia Treatment
11. Community-Acquired Bacterial Pneumonia Marketed Therapies
12. Community-Acquired Bacterial Pneumonia Emerging Drugs and Latest Therapeutic Advances
13. Community-Acquired Bacterial Pneumonia Seven Major Market Analysis
14. Attribute Analysis
15. Community-Acquired Bacterial Pneumonia Market Outlook (In US, EU5, and Japan)
16. Community-Acquired Bacterial Pneumonia Companies Active in the Market
17. Community-Acquired Bacterial Pneumonia Access and Reimbursement Overview
18. KOL Views on the Community-Acquired Bacterial Pneumonia Market
19. Community-Acquired Bacterial Pneumonia Market Drivers
20. Community-Acquired Bacterial Pneumonia Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Seborrhea Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Seborrhea market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Seborrhea market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States